Overall, STI-8811 is a BCMA-targeting ADC with unique binding properties that demonstrates excellent tumor growth inhibition and regression under conditions that challenge current clinical BCMA-targeting ADCs while maintaining low toxicity and a favorable safety profile. The gene discussed is TNFRSF17; the disease is neoplasm.